Dr. Sundas Khan
Overview
Sundas Khan is a Hematologist and an Oncologist in Lancaster, Pennsylvania. Dr. Khan is rated as an Advanced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are DICER1 Syndrome, HER2 Negative Breast Cancer, BRCA Positive Breast Cancer, and Familial Colorectal Cancer. Dr. Khan is currently accepting new patients.
Her clinical research consists of co-authoring 1 peer reviewed article. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- MEDICARE PDP
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE SNP
- OTHER MEDICARE PART D
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
2102 Harrisburg Pike, Lancaster, PA 17601
Additional Areas of Focus
Dr. Khan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Rena Rowan Breast Center
Susan Domchek is an Oncologist in Philadelphia, Pennsylvania. Dr. Domchek is rated as an Elite provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Breast Cancer, Ovarian Cancer, BRCA Positive Breast Cancer, Salpingo-Oophorectomy, and Hormone Replacement Therapy (HRT). Dr. Domchek is currently accepting new patients.
Rena Rowan Breast Center
Kara Maxwell is an Oncologist in Philadelphia, Pennsylvania. Dr. Maxwell is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Li-Fraumeni Syndrome, Breast Cancer, Prostate Cancer, and BRCA Positive Breast Cancer. Dr. Maxwell is currently accepting new patients.
Rena Rowan Breast Center
Payal Shah is an Oncologist in Philadelphia, Pennsylvania. Dr. Shah has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, BRCA Positive Breast Cancer, and Bone Marrow Aspiration. Dr. Shah is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- DICER1 SyndromeDr. Khan isAdvanced. Learn about DICER1 Syndrome.
- Experienced
- Atypical Hemolytic Uremic Syndrome (aHUS)
- BRCA Positive Breast CancerDr. Khan isExperienced. Learn about BRCA Positive Breast Cancer.
- D-Plus Hemolytic Uremic SyndromeDr. Khan isExperienced. Learn about D-Plus Hemolytic Uremic Syndrome.
- Familial Colorectal CancerDr. Khan isExperienced. Learn about Familial Colorectal Cancer.
- Hemolytic-Uremic SyndromeDr. Khan isExperienced. Learn about Hemolytic-Uremic Syndrome.
- HER2 Negative Breast CancerDr. Khan isExperienced. Learn about HER2 Negative Breast Cancer.